Business Context and Reporting Period
This Form 8-K is filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on November 7, 2019. The filing serves to report the company's financial results for the three- and nine-month periods ended September 30, 2019, as detailed in a press release attached as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1), which is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text of the 8-K itself. Investors must refer to the attached press release for comparative financial data and analysis of changes.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, or risk factors. The registrant is identified as an emerging growth company. The press release attached as Exhibit 99.1 contains the full management commentary and any forward-looking statements.
Important Facts for Investors to Verify
- Verify the specific financial results (revenue, net loss, cash position) in the attached Exhibit 99.1 press release, as the 8-K text only references the report.
- Confirm the company name is Miragen Therapeutics, Inc. (Ticker: MGEN), noting the discrepancy with the "Viridian Therapeutics" name in the request metadata.
- Note that the press release is not deemed "filed" under Section 18 of the Exchange Act, meaning it is not subject to the same liabilities as the 8-K itself.
- Review the company's status as an emerging growth company for potential differences in financial reporting standards.